Annual Cash & Cash Equivalents
$635.37 M
+$258.83 M+68.74%
31 March 2024
Summary:
Immunovant annual cash & cash equivalents is currently $635.37 million, with the most recent change of +$258.83 million (+68.74%) on 31 March 2024. During the last 3 years, it has risen by +$235.22 million (+58.78%). IMVT annual cash & cash equivalents is now at all-time high.IMVT Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$472.94 M
-$87.06 M-15.55%
30 September 2024
Summary:
Immunovant quarterly cash and cash equivalents is currently $472.94 million, with the most recent change of -$87.06 million (-15.55%) on 30 September 2024. Over the past year, it has increased by +$203.01 million (+75.21%). IMVT quarterly cash and cash equivalents is now -31.55% below its all-time high of $690.94 million, reached on 31 December 2023.IMVT Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IMVT Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +68.7% | +75.2% |
| 3 y3 years | +58.8% | -15.4% |
| 5 y5 years | +10000.0% | +10000.0% |
IMVT Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +68.7% | -31.6% | +75.2% |
| 5 y | 5 years | at high | >+9999.0% | -31.6% | >+9999.0% |
| alltime | all time | at high | >+9999.0% | -31.6% | >+9999.0% |
Immunovant Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $472.94 M(-15.5%) |
| June 2024 | - | $560.00 M(-11.9%) |
| Mar 2024 | $635.37 M(+68.7%) | $635.37 M(-8.0%) |
| Dec 2023 | - | $690.94 M(+156.0%) |
| Sept 2023 | - | $269.93 M(-18.2%) |
| June 2023 | - | $329.96 M(-12.4%) |
| Mar 2023 | $376.53 M(-23.8%) | $376.53 M(-13.0%) |
| Dec 2022 | - | $432.61 M(+6.6%) |
| Sept 2022 | - | $405.77 M(-5.0%) |
| June 2022 | - | $427.20 M(-13.5%) |
| Mar 2022 | $493.82 M | $493.82 M(-6.3%) |
| Dec 2021 | - | $527.00 M(-5.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2021 | - | $558.95 M(+47.5%) |
| June 2021 | - | $379.00 M(-5.3%) |
| Mar 2021 | $400.15 M(+297.9%) | $400.15 M(-5.2%) |
| Dec 2020 | - | $421.97 M(-5.0%) |
| Sept 2020 | - | $444.37 M(+58.5%) |
| June 2020 | - | $280.28 M(+178.7%) |
| Mar 2020 | $100.57 M(>+9900.0%) | $100.57 M(-18.6%) |
| Dec 2019 | - | $123.53 M(+7571.2%) |
| Sept 2019 | - | $1.61 M(-15.8%) |
| June 2019 | - | $1.91 M(+1193.6%) |
| Mar 2019 | - | $147.80 K |
| Dec 2018 | $325.00 K | - |
FAQ
- What is Immunovant annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Immunovant?
- What is Immunovant annual cash & cash equivalents year-on-year change?
- What is Immunovant quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Immunovant?
- What is Immunovant quarterly cash and cash equivalents year-on-year change?
What is Immunovant annual cash & cash equivalents?
The current annual cash & cash equivalents of IMVT is $635.37 M
What is the all time high annual cash & cash equivalents for Immunovant?
Immunovant all-time high annual cash & cash equivalents is $635.37 M
What is Immunovant annual cash & cash equivalents year-on-year change?
Over the past year, IMVT annual cash & cash equivalents has changed by +$258.83 M (+68.74%)
What is Immunovant quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of IMVT is $472.94 M
What is the all time high quarterly cash and cash equivalents for Immunovant?
Immunovant all-time high quarterly cash and cash equivalents is $690.94 M
What is Immunovant quarterly cash and cash equivalents year-on-year change?
Over the past year, IMVT quarterly cash and cash equivalents has changed by +$203.01 M (+75.21%)